Lack of Effect of Acute Repaglinide Administration on Postprandial Lipaemia in Patients with Type 2 Diabetes Mellitus

Abstract

The effect of acute repaglinide administration (2 mg) on postprandial glycaemia and lipaemia has been examined in 20 subjects with type 2 diabetes mellitus. Each subject received in the morning, after a 12 to 14 h fast, a standard mixed meal (total energy 783 kcal), preceded by one tablet of 2 mg repaglinide or placebo. Chylomicrons and chylomicron-deficient plasma were prepared by ultracentrifugation. Triglyceride levels in CM fraction (CM-triglycerides) in total plasma as well as in CM-deficient plasma (non-CM-triglycerides) were determined. A significant reduction in postprandial glycaemia was observed after repaglinide administration compared to placebo (p < 0.001). Plasma concentrations of total triglycerides, CM-triglycerides, non-CM-triglycerides, free fatty acids and the other plasma lipids measured, were not significantly different between the two phases of the study. It is concluded that, in contrast to sulphonylureas, acute repaglinide administration does not improve postprandial lipaemia in patients with type 2 diabetes.

Key words

Repaglinide - type 2 diabetes mellitus - triglycerides - postprandial triglyceridaemia - lipoprotein subfractions

References

• 1 Chen Y D, Swami S, Skowronski R, Coulston A, Reaven G M. Differences in postprandial lipaemia between patients with normal glucose tolerance and noninsulin-dependent diabetes mellitus.  J Clin Endocrinol Metab. 1993;  76 172-177
• 2 Damsbo P, Marbury T C, Hatorp V, Clauson P, Muller P G. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.  Diabetes Res Clin Pract. 1999;  45 31-39
• 3 De Man F H, Cabezas M C, Van Barlingen H H, Erkelens D W, de Bruin T W. Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis.  Eur J Clin Invest. 1996;  26 89-108
• 4 Jeppesen J, Zhou M Y, Chen Y D, Reaven G M. Effect of glipizide treatment on postprandial lipaemia in patients with NIDDM.  Diabetologia. 1994;  37 781-787
• 5 Katsilambros N. Postprandial triglyceridaemia.  Diabet Med. 1995;  12 451-452
• 6 Malaisse W J. Mechanism of action of new class of insulin secretagogues.  Exp Clin Endocrinol Diabetes. 1999;  107 (Suppl 4) S140-S143
• 7 Mohanlal N, Holman R R. The effect of nateglinide stimulated insulin secretion on post challenge glucose and lipid metabolism in type 2 diabetes mellitus.  Diabetologia. 2002;  45 (Suppl 2) A768
• 8 Skrapari I, Perrea D, Ioannidis I, Karabina S AP, Elisaf M, Tselepis A D, Karagiannacos P, Katsilambros N. Glibenclimide improves postprandial hypertriglyceridaemia in Type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels.  Diabet Med. 2001;  18 781-785
• 9 Taskinen M R, Beltz W F, Harper I, Fields R M, Schonfeld G, Grundy S M, Howard B V. Effects of NIDDM on very-low-density lipoprotein triglycerides and apolipoprotein B metabolism. Studies before and after sulfonylurea therapy.  Diabetes. 1986;  35 1268-1277
• 10 Taskinen M R. Pathogenesis of dyslipidemia in type 2 diabetes.  Exp Clin Endocrinol Diabetes. 2001;  109 (Suppl 2) S180-S188
• 11 Wolffenbuttel B H, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.  Diabetes Care. 1999;  22 463-467